Literature DB >> 2878344

Adverse reactions to beta 2-agonist bronchodilators.

K M Lulich, R G Goldie, G Ryan, J W Paterson.   

Abstract

Beta 2-Agonists are safe and effective bronchodilator drugs. Their major adverse effects of skeletal muscle tremor, tachycardia and various metabolic effects are mediated by beta-adrenoceptor stimulation and are reversible. Skeletal muscle tremor is the most frequent dose-limiting side effect. It may be reduced by commencing treatment with a low dose and if it persists another beta 2-agonist may be tried. Other side effects such as cardiac arrhythmias and reduction in PaO2 are a serious potential problem in some susceptible asthmatics. However, they are infrequent or of a mild degree and are generally outweighed by the good control of asthma produced by beta 2-agonists. Side effects from beta 2-agonist therapy can be minimised by use of the inhaled route which selectively delivers the drug to the airways. Furthermore, selective tolerance develops to their side effects. The dose of a beta 2-agonist should be assessed on the basis of therapeutic effect and the level of tolerance to its side effects. Recommended doses of beta 2-agonists used for long term therapy do not cause clinically significant desensitisation of airway beta-adrenoceptors, although this may become a relevant problem in patients who are regularly receiving very high doses. Intravenous beta 2-agonists have a place in the treatment of severe asthma not responding to nebuliser therapy. In this life-threatening situation with severe airflow obstruction, monitoring of heart rate, PaO2, plasma potassium and the electrocardiogram should be mandatory and supplemental oxygen given so that serious adverse effects are presented.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878344     DOI: 10.1007/bf03259844

Source DB:  PubMed          Journal:  Med Toxicol        ISSN: 0112-5966


  96 in total

1.  Overdose of salbutamol.

Authors:  G W Morrison; M J Farebrother
Journal:  Lancet       Date:  1973-09-22       Impact factor: 79.321

2.  Epinephrine-induced hypokalemia: relation to liver and skeletal muscle.

Authors:  R L Vick; E P Todd; D W Luedke
Journal:  J Pharmacol Exp Ther       Date:  1972-04       Impact factor: 4.030

3.  Deaths in asthma: disease or treatment?

Authors:  C J Stewart; A J Nunn; D Stableforth; A R Somner
Journal:  Lancet       Date:  1981-10-03       Impact factor: 79.321

4.  Bronchodilators, hypokalaemia, and fatal asthma.

Authors:  K R Chapman; A S Rebuck
Journal:  Lancet       Date:  1985-07-20       Impact factor: 79.321

5.  Hemodynamic effects of an inhaled beta-2 agonist.

Authors:  K R Chapman; D L Smith; A S Rebuck; F H Leenen
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

6.  Cardiopulmonary effects of terbutaline and a bronchodilator combination in chronic obstructive pulmonary disease.

Authors:  D J Pierson; L D Hudson; K Stark; M Hedgecock
Journal:  Chest       Date:  1980-02       Impact factor: 9.410

7.  Blood concentrations in man of fluorinated hydrocarbons after inhalation of pressurised aerosols.

Authors:  C T Dollery; D S Davies; G H Draffan; F M Williams; M E Conolly
Journal:  Lancet       Date:  1970-12-05       Impact factor: 79.321

8.  Domiciliary nebulized beta-agonists. Long-term treatment in asthmatics, and drug intake and plasma levels in acute asthma.

Authors:  J Boe
Journal:  Eur J Respir Dis Suppl       Date:  1984

9.  Inhaled salbutamol (albuterol) vs injected epinephrine in the treatment of acute asthma in children.

Authors:  A B Becker; N A Nelson; F E Simons
Journal:  J Pediatr       Date:  1983-03       Impact factor: 4.406

10.  Oxygen as a driving gas for nebulisers: safe or dangerous?

Authors:  K A Gunawardena; B Patel; I A Campbell; J B MacDonald; A P Smith
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-28
View more
  8 in total

1.  Inhibition of tracheal vascular extravasation by liposome-encapsulated albuterol in rats.

Authors:  W Zhang; L Guo; J A Nadel; D Papahadjopoulos
Journal:  Pharm Res       Date:  1998-03       Impact factor: 4.200

2.  Bronchodilator therapy and hyperactivity in preschool children.

Authors:  I Hadjikoumi; P Loader; M Bracken; A D Milner
Journal:  Arch Dis Child       Date:  2002-03       Impact factor: 3.791

3.  Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma.

Authors:  Piotr Kuna; Joanna Jerzynska; Matteo Martini; Andrea Vele; Irene Barneschi; Fabrizia Mariotti; George Georges; Giorgia Ciurlia
Journal:  Pharmacol Res Perspect       Date:  2022-08

4.  Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study.

Authors:  Joseph Emil Amegadzie; John-Michael Gamble; Jamie Farrell; Zhiwei Gao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-05-20

Review 5.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

6.  Salbutamol-Induced QT Interval Prolongation in a Two-Year-Old Patient.

Authors:  Mohamed Elgassim; Amro Abdelrahman; Amin Saied Sanosi Saied; Amina T Ahmed; Mustafa Osman; Malik Hussain; Ibtesam AlJaufi; Waleed Salem
Journal:  Cureus       Date:  2022-02-04

7.  Safety of indacaterol in the treatment of patients with COPD.

Authors:  James F Donohue; Dave Singh; Oliver Kornmann; David Lawrence; Cheryl Lassen; Benjamin Kramer
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-09-22

8.  Salbutamol Abuse is Associated with Ventricular Fibrillation.

Authors:  Emin Uysal; Suleyman Solak; Murat Carus; Nedim Uzun; Erdem Cevik
Journal:  Turk J Emerg Med       Date:  2016-03-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.